PRQR
NASDAQProQR Therapeutics N.V.
News · 26 weeks500%
2026-02-012026-07-26
Mix2590d
- SEC Filings10(40%)
- Other7(28%)
- Insider7(28%)
- Offering1(4%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by ProQR Therapeutics N.V.SCHEDULE 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
- INSIDERDirector Filius Bart bought $257,925 worth of Ordinary Shares (150,000 units at $1.72), increasing direct ownership by 100% to 300,000 units (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form EFFECT filed by ProQR Therapeutics N.V.EFFECT - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 424B5 filed by ProQR Therapeutics N.V.424B5 - ProQR Therapeutics N.V. (0001612940) (Filer)
- INSIDERChief Executive Officer De Boer Daniel Anton bought $261,000 worth of Ordinary Shares (150,000 units at $1.74), increasing direct ownership by 100% to 300,000 units (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERChief Executive Officer De Boer Daniel Anton bought $238,500 worth of Ordinary Shares (150,000 units at $1.59) (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form F-3 filed by ProQR Therapeutics N.V.F-3 - ProQR Therapeutics N.V. (0001612940) (Filer)
- INSIDERAmendment: SEC Form 4 filed by Director Hinsch Gylvin Lykke4/A - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERDirector Filius Bart bought $231,000 worth of Ordinary Shares (150,000 units at $1.54) (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 424B5 filed by ProQR Therapeutics N.V.424B5 - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private PlacementLEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the "Offering") at an offering price of $1.81 per share (the "Offering Price"), for total gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. Concurrently with the Offering, ProQR has entered into a
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing PlatformData from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated up to 8-fold change (6 mg/kg) in total bile acids in serum, exceeding the 2-fold threshold identified by the Company as a meaningful indicator of NTCP modulation, along with concordant readouts of bile acid profile and TUDCA markersFavorable safety and tolerability profile observed with AX-0810 to date, with no serious adverse events or pruritus reported; pharmacokinetic findings to date support sustained target engagement, including a half-life of eight weeksThe NTCP biomarker findings support ad
- INSIDERSEC Form 4 filed by Director Hinsch Gylvin Lykke4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hinsch Gylvin Lykke3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces First Quarter 2026 Operating and Financial ResultsAX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indicationPipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalystsContinued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory BoardEnded Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives throu
- PRProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing PlatformLEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced presentations at several upcoming scientific conferences, highlighting continued progress in the application of its Axiomer RNA editing platform. "These presentations collectively expand the body of evidence supporting the potential of our Axiomer RNA editing platform to enable precise RNA editing across multiple targets," said Gerard Platenburg, Co-founder and Chief Scientific Officer of ProQR. "Acro
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Tuesday, June 2, 2026 at 1500 CEST at the offices of Allen Overy Shearman Sterling LLP, in Amsterdam, the Netherlands. All relevant documents and information for the meeting, including the notice and agenda and explanatory notes, are or will be made available in the "Investors & Media" section of ProQR's website (www.proqr.com) under
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsLEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, to its Board of Directors. "We are pleased to nominate Lykke to our Board of Directors," said James Shannon, MD, Chairperson of the Board of ProQR Therapeutics. "Her extensive experience in global drug development and broad perspective across therapeutic areas will complement t
PRQR FAQ
7 questionsWhat does ProQR Therapeutics N.V. do?
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial...Where does PRQR stock trade?
ProQR Therapeutics N.V. (PRQR) is listed on NASDAQ.What sector and industry is PRQR in?
ProQR Therapeutics N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ProQR Therapeutics N.V. go public?
ProQR Therapeutics N.V. (PRQR) completed its IPO in 2014.What are analysts saying about PRQR?
ProQR Therapeutics N.V. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $900.00 price target on 2026-03-12.What companies are similar to PRQR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PRQR side-by-side with any of them on Quantisnow.How can I track PRQR on Quantisnow?
Quantisnow aggregates ProQR Therapeutics N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRQR to receive live email and push alerts on every new disclosure.